Edition:
India

Loxo Oncology Inc (LOXO.OQ)

LOXO.OQ on NASDAQ Stock Exchange Global Market

133.06USD
20 Apr 2018
Change (% chg)

$-0.39 (-0.29%)
Prev Close
$133.45
Open
$132.98
Day's High
$134.19
Day's Low
$131.80
Volume
71,871
Avg. Vol
153,706
52-wk High
$138.53
52-wk Low
$42.11

Select another date:

Wed, Apr 11 2018

BRIEF-Veracyte Announces Precision Medicine Collaboration With Loxo Oncology

* VERACYTE ANNOUNCES PRECISION MEDICINE COLLABORATION WITH LOXO ONCOLOGY

Loxo, Illumina to partner for diagnostic tool targeting cancer

Drug developer Loxo Oncology said on Tuesday it is partnering with genetic testing company Illumina Inc on a diagnostic tool that will work with Loxo's larotrectinib and another one of its experimental cancer drugs, across tumor types.

UPDATE 1-Loxo, Illumina to partner for diagnostic tool targeting cancer

April 10 Drug developer Loxo Oncology said on Tuesday it is partnering with genetic testing company Illumina Inc on a diagnostic tool that will work with Loxo's larotrectinib and another one of its experimental cancer drugs, across tumor types.

Loxo and Illumina in partnership over diagnostic for cancer drug

Loxo Oncology is partnering with genetic testing company Illumina Inc to use Illumina's diagnostic tool alongside larotrectinib, the drug developer's potential blockbuster drug, the companies said on Tuesday.

Loxo and Illumina in partnership over diagnostic for cancer drug

April 10 Loxo Oncology is partnering with genetic testing company Illumina Inc to use Illumina's diagnostic tool alongside larotrectinib, the drug developer's potential blockbuster drug, the companies said on Tuesday.

BRIEF-Loxo Oncology And Illumina To Partner On Developing Pan Cancer Companion Diagnostics

* LOXO ONCOLOGY AND ILLUMINA TO PARTNER ON DEVELOPING NEXT-GENERATION SEQUENCING-BASED PAN-CANCER COMPANION DIAGNOSTICS

High-flying biotech Loxo tempers bullish view for cancer drug

STAMFORD, Connecticut In record time, Loxo Oncology developed a novel drug for a wide variety of tumors that share a rare mutation. It recently struck a partnership with Germany's Bayer . Its stock tripled in the past year.

FOCUS-High-flying biotech Loxo tempers bullish view for cancer drug

STAMFORD, Connecticut, April 3 In record time, Loxo Oncology developed a novel drug for a wide variety of tumors that share a rare mutation. It recently struck a partnership with Germany's Bayer. Its stock tripled in the past year.

BRIEF-Loxo Oncology Completes Rolling Submission Of New Drug Application To U.S. Food And Drug Administration

* LOXO ONCOLOGY COMPLETES ROLLING SUBMISSION OF NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR LAROTRECTINIB FOR THE TREATMENT OF TRK FUSION CANCER Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Loxo Oncology Reports Quarterly Non-Gaap Net Loss Per Share $1.24

* LOXO ONCOLOGY REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS

Select another date: